Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Guided Therapeutics (GTHP) Long-Term Debt Issuances (2016 - 2025)

Guided Therapeutics' Long-Term Debt Issuances history spans 13 years, with the latest figure at $108000.0 for Q3 2025.

  • For Q3 2025, Long-Term Debt Issuances fell 3.57% year-over-year to $108000.0; the TTM value through Sep 2025 reached $663000.0, up 112.5%, while the annual FY2024 figure was $512000.0, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q3 2025 was $108000.0 at Guided Therapeutics, down from $150000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.4 million in Q3 2022 and bottomed at -$1.4 million in Q4 2022.
  • The 4-year median for Long-Term Debt Issuances is $175000.0 (2024), against an average of $117900.0.
  • The largest YoY upside for Long-Term Debt Issuances was 233.72% in 2022 against a maximum downside of 211.86% in 2022.
  • A 4-year view of Long-Term Debt Issuances shows it stood at $1.2 million in 2021, then crashed by 211.86% to -$1.4 million in 2022, then soared by 114.33% to $200000.0 in 2024, then plummeted by 46.0% to $108000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Long-Term Debt Issuances are $108000.0 (Q3 2025), $150000.0 (Q2 2025), and $205000.0 (Q1 2025).